Ultragenyx Pharmaceutical, Inc. (RARE) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The phase 3 study “Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia” tests Ultragenyx’s DTX401 gene therapy in a rare liver disease with high unmet need. It aims to cut or remove the need for constant glucose treatment and improve day-to-day blood sugar control, a goal that could reshape care if results are strong.
The treatment is a one-time IV gene therapy called DTX401, also known as pariglasgene brecaparvovec, designed to help the liver make a key enzyme that is missing in this disease. Patients also receive short-term oral steroids or placebo to manage immune reactions, while placebo infusions serve as a control for comparison.
The trial is interventional and randomized, meaning patients were assigned to treatment or placebo by chance. It uses a crossover, double-blind design so both patients and doctors are unaware of who gets DTX401 first, and everyone is expected to receive active therapy over time, with the main goal being better disease control.
The study began after first submission on July 14, 2021, marking the move into late-stage testing. The trial is now listed as completed, and the last update was posted on March 23, 2026, which signals recent activity and suggests data may be close to, or in the process of, public disclosure.
For investors, a completed phase 3 in an ultra-rare disorder is a key value catalyst for Ultragenyx (RARE), as positive data could support regulatory filings and eventual revenue in a niche but high-priced market. The update also matters in the wider gene therapy space, where peers like Biomarin and other AAV-focused firms are competing, and clear efficacy and safety could lift sector sentiment.
The study has been updated and is now marked as completed, with further details available on the ClinicalTrials portal.
To learn more about RARE’s potential, visit the Ultragenyx Pharmaceutical, Inc. drug pipeline page.